TY - JOUR
T1 - Persistent or recurrent bronchogenic carcinoma
T2 - Detection with PET and 2-[F-18]-2-deoxy-D-glucose1
AU - Patz, Edward F.
AU - Lowe, Val J.
AU - Hoffman, John M.
AU - Paine, Susan S.
AU - Harris, Laura K.
AU - Goodman, Philip C.
PY - 1994/5
Y1 - 1994/5
N2 - PURPOSE: To assess positron emission tomography (PET) with 2-[fluorine-18]-2-deoxy-D-glucose (FDG) in the differentiation of recurrent bronchogenic carcinoma from fibrosis after therapy. MATERIALS AND METHODS: Any patient treated for bronchogenic carcinoma who had a residual chest radiographic abnormality was eligible. Forty-three patients (mean age, 63.5 years) participated. Chest radiographs and thoracic computed tomographic scans helped localize the abnormality prior to PET. Semiquantitative analysis was performed on FDG PET images with calculated standardized uptake ratios (SURs). Sensitivity, specificity, and confidence intervals for recurrent disease were determined. RESULTS: Thirty-five patients had recurrent or persistent tumor (median SUR, 7.6; range, 1.9-18.7). Eight patients had fibrosis but no evidence of disease (SUR, 1.6; range, 0.6-2.4). The sensitivity for detecting recurrent tumor (SUR > 2.5) was 97.1%, and specificity was 100%. The SUR for recurrent tumor was statistically significantly higher than for fibrosis (P = .0001). CONCLUSION: FDG PET accurately helps differentiate recurrent bronchogenic carcinoma from fibrosis.
AB - PURPOSE: To assess positron emission tomography (PET) with 2-[fluorine-18]-2-deoxy-D-glucose (FDG) in the differentiation of recurrent bronchogenic carcinoma from fibrosis after therapy. MATERIALS AND METHODS: Any patient treated for bronchogenic carcinoma who had a residual chest radiographic abnormality was eligible. Forty-three patients (mean age, 63.5 years) participated. Chest radiographs and thoracic computed tomographic scans helped localize the abnormality prior to PET. Semiquantitative analysis was performed on FDG PET images with calculated standardized uptake ratios (SURs). Sensitivity, specificity, and confidence intervals for recurrent disease were determined. RESULTS: Thirty-five patients had recurrent or persistent tumor (median SUR, 7.6; range, 1.9-18.7). Eight patients had fibrosis but no evidence of disease (SUR, 1.6; range, 0.6-2.4). The sensitivity for detecting recurrent tumor (SUR > 2.5) was 97.1%, and specificity was 100%. The SUR for recurrent tumor was statistically significantly higher than for fibrosis (P = .0001). CONCLUSION: FDG PET accurately helps differentiate recurrent bronchogenic carcinoma from fibrosis.
KW - Lung neoplasms, diagnosis, 60.32
KW - Lung neoplasms, emission CT (ECT), 60.12163
KW - Lung, fibrosis, 60.47
UR - http://www.scopus.com/inward/record.url?scp=0028325906&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028325906&partnerID=8YFLogxK
U2 - 10.1148/radiology.191.2.8153309
DO - 10.1148/radiology.191.2.8153309
M3 - Article
C2 - 8153309
AN - SCOPUS:0028325906
SN - 0033-8419
VL - 191
SP - 379
EP - 382
JO - Radiology
JF - Radiology
IS - 2
ER -